摘要
为研究我国非何杰金淋巴瘤（NHL）患者bcl－2基因重排的发生情况，以及其可能的临床应用价值，应用半套式聚合酶链反应（semi－nestedPCR）检测45例非何杰金淋巴瘤bcl-2／JH融合基因，发现12例阳性，其中15例滤泡性淋巴瘤中有9例阳性（60％）；30例弥漫性淋巴瘤中3例阳性（10％），5例反应性淋巴组织增生者阴性。并发现bcl-2基因断裂点绝大部分位于主要断裂区（11／1291．7％），少数位于次要断裂区（1／12，8．3％）。结果提示，形成bcl-2／JH融基因是B细胞非何杰金淋巴瘤发生的重要病因，检测bcl－2／JH融合基因对鉴别淋巴组织的良恶性增生、明确克隆来源，提示预后及检测微小残留病灶均有重要意义。
To study the incidence and clinical significance of bcl-2/JH fusion in 45 Chinese patients with non-Hodgkin's lyrnphoma, semi-nested polymerase chain reaction (PCR) was used to detect the fusion gene of non-Hodgkin's lymphoma. A total of l2 patients gave positive results, they include 9 of the 15 patients with follicular lymphoma and 3 of the 30 patients with diffuse B-cell lymphoma. The results were negative in 5 patients with reactive hyperplasia. The breakpoint was located within the major breakpolnt region in 11 of the 12 patients, and the remaining patient had bcl-2 translocation in the rninor cluster region. The results of the study show that bcl-2/JH fusion gene in non-Hodgkin's lym phomas is an important molecular biological marker and has a significant role in differentlating benign or malignant hyperplasia, determination of clonality, predicting prognosis and in the discovery of minor residual disease.
出处
《中华病理学杂志》
CAS
CSCD
北大核心
1996年第3期152-154,共3页
Chinese Journal of Pathology
基金
铁道部优秀青年教师基金
